Fibrogen INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

16 Mar 2026

FGEN

10-K: Kyntra Bio Rebrands, Divests China Ops, Advances Oncology & MDS Programs

Kyntra Bio, formerly FibroGen, completed the sale of its China operations for $220.4 million, significantly improving liquidity while advancing its oncology and myelodysplastic syndromes pipeline.

17 Mar 2025

FGEN

Fibrogen INC

10-K: FibroGen Faces Going Concern Uncertainty Despite Roxadustat Growth and China Asset Sale

FibroGen's 10-K filing reveals a company in transition, balancing the potential of its oncology pipeline and roxadustat commercialization with significant financial challenges and strategic shifts.

26 Feb 2024

FGEN

Fibrogen INC

10-K: FibroGen's 2023 Annual Report: Focus on Pancreatic Cancer Trials and Roxadustat Growth

FibroGen's 2023 annual report highlights progress in pancreatic cancer trials, roxadustat sales growth in China, and strategic pipeline advancements.